Sarepta Therapeutics publishing Ebola, Marburg study results

Two experimental compounds to prevent the spread of the Ebola and Marburg viruses showed promise in recent initial human testing by Sarepta Therapeutics Inc.

In two separate studies, 30 healthy adult volunteers were given up to 9 milligrams of AVI-6002, intended for the prevention of Ebola, or AVI-6004, to combat the Marburg virus. The volunteers experienced no negative side effects and tolerated the drugs well.

Earlier testing done on non-human primates showed that the compounds prevented the development of the Ebola and Marburg viruses.

"We believe these promising early clinical safety results, coupled with the strong safety and efficacy data generated from animal studies ...  reinforce the use of our PMOplus chemistry platform to pursue potential treatments for deadly infectious diseases such as Ebola and Marburg," Michael Wong, senior medical director, infectious diseases at Sarepta Therapeutics, said. "These compounds have protected up to 80 to 100 percent of the non-human primates to Ebola and Marburg virus challenge infections, respectively."

The results of the studies will be published in the November issue of the American Society for Microbiology's journal "Antimicrobial Agents and Chemotherapy."